ATLANTIS trial: Results for patients treated within 3 hours of stroke onset

Gregory W. Albers; Wayne M. Clark; Kenneth P. Madden; Scott A. Hamilton

doi:10.1161/hs0202.102599

ATLANTIS trial: Results for patients treated within 3 hours of stroke onset

Gregory W. Albers, Wayne M. Clark, Kenneth P. Madden, Scott A. Hamilton

Neurology

Research output: Contribution to journal › Article › peer-review

201 Scopus citations

Abstract

Background and Purpose - Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. Methods - We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of symptom onset. Results - Despite a significant increase in the rate of symptomatic intracranial hemorrhage, tPA-treated patients were more likely to have a very favorable outcome (score of ≤1) on the National Institutes of Health Stroke Scale at 90 days (P=0.01). Conclusions - These data support current recommendations to administer intravenous tPA to eligible ischemic stroke patients who can be treated within 3 hours of symptom onset.

Original language	English (US)
Pages (from-to)	493-495
Number of pages	3
Journal	Stroke
Volume	33
Issue number	2
DOIs	https://doi.org/10.1161/hs0202.102599
State	Published - 2002

Keywords

Stroke, acute
Thrombolysis
Tissue plasminogen activator

ASJC Scopus subject areas

Clinical Neurology
Cardiology and Cardiovascular Medicine
Advanced and Specialized Nursing

Access to Document

10.1161/hs0202.102599

Cite this

@article{63fb694c8749405f95a1fdc10fe0440e,

title = "ATLANTIS trial: Results for patients treated within 3 hours of stroke onset",

abstract = "Background and Purpose - Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. Methods - We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of symptom onset. Results - Despite a significant increase in the rate of symptomatic intracranial hemorrhage, tPA-treated patients were more likely to have a very favorable outcome (score of ≤1) on the National Institutes of Health Stroke Scale at 90 days (P=0.01). Conclusions - These data support current recommendations to administer intravenous tPA to eligible ischemic stroke patients who can be treated within 3 hours of symptom onset.",

keywords = "Stroke, acute, Thrombolysis, Tissue plasminogen activator",

author = "Albers, {Gregory W.} and Clark, {Wayne M.} and Madden, {Kenneth P.} and Hamilton, {Scott A.}",

year = "2002",

doi = "10.1161/hs0202.102599",

language = "English (US)",

volume = "33",

pages = "493--495",

journal = "Stroke",

issn = "0039-2499",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - ATLANTIS trial

T2 - Results for patients treated within 3 hours of stroke onset

AU - Albers, Gregory W.

AU - Clark, Wayne M.

AU - Madden, Kenneth P.

AU - Hamilton, Scott A.

PY - 2002

Y1 - 2002

N2 - Background and Purpose - Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. Methods - We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of symptom onset. Results - Despite a significant increase in the rate of symptomatic intracranial hemorrhage, tPA-treated patients were more likely to have a very favorable outcome (score of ≤1) on the National Institutes of Health Stroke Scale at 90 days (P=0.01). Conclusions - These data support current recommendations to administer intravenous tPA to eligible ischemic stroke patients who can be treated within 3 hours of symptom onset.

AB - Background and Purpose - Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients. Methods - We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of symptom onset. Results - Despite a significant increase in the rate of symptomatic intracranial hemorrhage, tPA-treated patients were more likely to have a very favorable outcome (score of ≤1) on the National Institutes of Health Stroke Scale at 90 days (P=0.01). Conclusions - These data support current recommendations to administer intravenous tPA to eligible ischemic stroke patients who can be treated within 3 hours of symptom onset.

KW - Stroke, acute

KW - Thrombolysis

KW - Tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=0036158585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036158585&partnerID=8YFLogxK

U2 - 10.1161/hs0202.102599

DO - 10.1161/hs0202.102599

M3 - Article

C2 - 11823658

AN - SCOPUS:0036158585

SN - 0039-2499

VL - 33

SP - 493

EP - 495

JO - Stroke

JF - Stroke

IS - 2

ER -

ATLANTIS trial: Results for patients treated within 3 hours of stroke onset

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this